News | September 17, 2025
Lilly to build $5 billion manufacturing facility in Virginia
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Subscribe To Our Newsletter & Stay Updated
